00:30 , Jan 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Gut control

As evidence mounts linking obesity to the microbiome, three independent studies have identified separate ways of harnessing gut microbiota to treat the condition. The spectrum of approaches, which involve a bacterial protein, a bacterial species...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

C16G2: Phase II data

A double-blind, U.S. Phase II trial in about 60 healthy adults showed that a dental tray application of a gel formulation of C16G2 was superior to a mouth rinse application and a gel formulation applied...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Financial News

C3 Jian completes venture financing

C3 Jian Inc. , Marina del Rey, Calif.   Business: Infectious, Diagnostic, Dental   Date completed: 3/17/14   Type: Venture financing   Raised: $60.5 million   Investors: Renaissance Holding; Delta Dental; existing investors; new investors...
23:29 , Mar 17, 2014 |  BC Extra  |  Financial News

C3 Jian raises $60.5 million in series D

C3 Jian Inc. (Marina del Rey, Calif.) raised $60.5 million in a series D round led by existing investor Renaissance Holding Company. New investor Delta Dental also participated along with other undisclosed new and existing...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

C16G2: Phase II started

C3 Jian began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate C16G2 for 7 days in about 60 healthy adults. The trial will evaluate gel and rinse applications of C16G2 administered using a dental...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

C16G2: Phase I data

A double-blind, dose-escalation, U.S. Phase I trial in 36 healthy volunteers showed that a single oral rinse of C16G2 led to no treatment-related, severe or serious reported adverse events. C3 Jian Inc. , Marina del...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Clinical News

C16G2: Completed Phase I enrollment

C3 Jian completed enrollment of 36 healthy volunteers in a double-blind, dose-escalation, U.S. Phase I trial to evaluate a single oral rinse of C16G2. C3 Jian Inc. , Marina del Rey, Calif.   Product: C16G2...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Financial News

C3 Jian completes venture financing

C3 Jian Inc. , Inglewood, Calif.   Business: Infectious, Diagnostic   Date completed: 2/27/12   Type: Venture financing   Raised: $30 million   Investors: Wyssta Investments; Renaissance Health Services; Corvesta   Note: C3 Jian raised...
02:16 , Feb 28, 2012 |  BC Extra  |  Financial News

C3 Jian raises $30 million

C3 Jian Inc. (Inglewood, Calif.) raised $30 million in a series C round from existing investors Wyssta Investments; Renaissance Health Services; and Corvesta. C3 Jian plans to submit an IND to FDA in April for...